Dogwood Therapeutics, Inc.
DWTX
$4.99
-$0.07-1.38%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 84.44% | 105.37% | 522.31% | 96.20% | -20.20% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 266.71% | 237.11% | 562.70% | 80.59% | -27.58% |
| Operating Income | -266.71% | -237.11% | -562.70% | -80.59% | 27.58% |
| Income Before Tax | -262.66% | -731.29% | -600.54% | -84.66% | 27.14% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -262.68% | -746.05% | -600.50% | -84.66% | 27.14% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -262.68% | -746.05% | -600.50% | -84.66% | 27.14% |
| EBIT | -266.71% | -237.11% | -562.70% | -80.59% | 27.58% |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | -73.82% | -404.08% | -339.17% | -27.02% | 41.42% |
| Normalized Basic EPS | -73.82% | -90.37% | -311.79% | -27.02% | 41.42% |
| EPS Diluted | -73.82% | -404.08% | -339.17% | -27.02% | 41.22% |
| Normalized Diluted EPS | -73.82% | -90.37% | -311.79% | -27.02% | 41.42% |
| Average Basic Shares Outstanding | 108.64% | 87.13% | 70.13% | 45.37% | 24.37% |
| Average Diluted Shares Outstanding | 108.64% | 87.13% | 70.13% | 45.37% | 24.37% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |